Background. Anti-bacterial monoclonal antibodies can serve as a new treatment modality for difficult to treat infections. AR-105 is a fully human IgG1 monoclonal antibody (mAb) that binds to an extracellular polysaccharide epitope of Pseudomonas aeruginosa (PA) and was shown to mediate in vitro complement-dependent opsonophagocytic killing. AR-105 is currently being tested in a global Phase 2 clinical trial as an adjunctive treatment to standard of care antibiotics in ventilator-associated pneumonia patients. Here we present pre-clinical efficacy and clinical safety data for AR-105.
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Background. WCK 5222 combines cefepime (FEP) with zidebactam (ZID), a bicycloacyl hydrazide β-lactam enhancer which binds PBP2 in PSA and inhibits class A and C β-lactamases. The in vivo efficacy of human-simulated bronchopulmonary exposures of WCK 5222 against MDR PSA, a recalcitrant pneumonia-causing pathogen with few treatment options, was investigated in a neutropenic murine pneumonia model.
Methods. Thirteen clinical isolates of MDR PSA with FEP MIC ≥64 mg/L were studied in neutropenic CD-1 mice. FEP, ZID, and WCK 5222 MICs were measured by broth microdilution in triplicate. For in vivo experiments, lungs were intranasally inoculated with 10 7 -10 8 CFU/mL bacterial suspensions. Human-simulated regimens (HSR) of FEP and ZID alone and in combination which achieved epithelial lining fluid (ELF) exposures in mice approximating human ELF exposures after doses of 2 g FEP/1 g ZID as a 1 hour infusion at steady state were developed. For each regimen, groups of 6 mice were dosed subcutaneously 2 hours after inoculation for 24 hours, then sacrificed. Vehicle-dosed control mice were sacrificed at the start (0 hour) and end (24 hours) of the dosing period. Lungs were aseptically harvested and bacterial CFU/lungs were determined.
Results. FEP MIC was >64 mg/L for all isolates, while ZID and WCK 5222 MICs ranged from 4-512 and 4-32 mg/L, respectively. Mean bacterial growth for all isolates at 0 hour was 6.68 log 10 CFU/lungs. Mean changes ± SD in bacterial density at 24 hours compared with 0 hour controls for 12 isolates with WCK5222 MIC ≤16 mg/L were 2.08 ± 1.09, 1.09 ± 0.98, −0.92 ± 1.45, and −2.13 ± 0.75, for control, FEP, ZID, and WCK5222, respectively. Against these isolates, ZID yielded >1 log 10 CFU/lungs reduction in 7/12, while activity was enhanced with WCK5222, producing >1 log 10 CFU/ lungs reduction in 11/12 and >2 log 10 CFU/lungs reduction in 9/12. All isolates showed growth or stasis on FEP.
Conclusion. Human-simulated bronchopulmonary exposures of WCK5222 is effective against MDR PSA at MIC up to 16 mg/L in a neutropenic murine model. These data support the clinical development of WCK5222 for the treatment of pseudomonal lung infections, but further studies of PSA with high WCK5222 MIC are necessary to delineate the susceptibility breakpoint.
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